Member Info for Parpaing

I don't think a "hold" rating is desperate. I'm just pleased that BIOM is making progress in a very difficult market. If the lignin project is successful and plastics can be made cheaper than oil-based plastics, then it will be a winner. Did you watch the video with Tim Bugg ?

http://www.biomebioplastics.com/research-confirms-next-generation-bioplastics-could-be-made-from-trees/

Check out BIOM website for the latest (9 June 2014). http://www.biomebioplastics.com/research-confirms-next-generation-bioplastics-could-be-made-from-trees/

Biome Bioplastics is conducting research into a new, plentiful source of organic chemicals for the manufacture of bioplastics that could significantly reduce costs, expand functionality and increase performance. Backed by a grant from the UK’s innovation agency, the Technology Strategy Board, and working in partnership with the University of Warwick’s Centre for Industrial Biotechnology and Biorefining, we are conducting a pioneering project to investigate the possibility of using lignin as an alternative, bio-based source of aromatic chemicals. The project has successfully demonstrated that bacteria can be effective in the selective degradation of lignin, and that the breakdown pathway can be controlled and improved using synthetic biology. Crucially, several organic chemicals have been produced at laboratory scale in promising yields that have potential use in bioplastic manufacture. Initial scale-up trials on several of these target chemicals have demonstrated the potential for them to be produced at industrial scale, suggesting the commercial feasibility of using lignin-derived chemicals as an alternative for their petrochemical counterparts. We have also transformed these chemicals into a material that shows promising properties for use as an advanced bioplastic. The next phase of the project will examine how the yields of these organic chemicals can be increased using different bacteria and explore options for further scale-up of this technology. The first commercial target is to use the lignin-derived chemicals to replace the oil-derived equivalents currently used to convey strength and flexibility in some of our products, further reducing cost and enhancing sustainability.

Durapipe is one of 97 companies in the international Aliaxis group. After successful field trials in the market place, Biome's portable induction welding equipment will have worldwide sales potential to fluid handling companies within the group and pipe installers. Coupled with transforming cheap lignin into a thermoplastic means that bioplastics will become cheaper than oil-based plastics. The future for BIOM is starting to look very rosy indeed.

Well done to the Paul Mines and team. Positive news. I look forward to seeing the equipment in the market.

The division announced the SUCCESSFUL completion of a feasibility study undertaken in conjunction with the University of Warwick's Centre for Biotechnology and Biorefining and supported by the Government-backed Technology Strategy Board (TSB). This means that BIOM are a step closer to producing cheaper plastics similar to fossil-fuel based plastics. This is excellent news.

to the BIOM team. Onwards and upwards.

Ineligible for quotation on OTCBB due to quoting inactivity under SEC Rule 15c2-11. XBIO now marked as "Private". Expect an RNS very soon - hopefully NASDAQ listing.

might be on Shire's shopping list...

tick up today - must be getting ready to Nasdaq our company.

A new program that lets drugmakers move more quickly through the approval process for breakthrough products may help lower the cost of life-saving treatments, the nation’s chief drug regulator said today. http://www.bloomberg.com/news/2014-05-28/drugs-can-reach-patients-faster-and-cheaper-fda-chief-says.html

be used as benchmark for the SP? When Sanofi took over Genzyme, Genzyme’s stockholders got $74 a share in cash, Plus, they also received so-called contingent value rights that entitle them to payments of as much as $14 a share depending on the performance of Genzyme’s experimental multiple-sclerosis drug Lemtrada and production levels of two other products.

As you know the restaurant food in Florida comes in size XXXL, the first language is Spanish and the obesity rate is 25.2 %. Florida is now the 12th least obese state in the nation. After three decades of increases, adult obesity rates remained level in every state except for Arkansas. However, rates remain high — Florida's adult obesity rate is 25.2 percent, up from 19.9 percent in 2003 and from 11.4 percent in 1990. Thirteen states now have adult obesity rates above 30 percent, 41 states have rates of at least 25 percent, and every state is above 20 percent. In 1980, no state was above 15 percent; in 1991, no state was above 20 percent; in 2000, no state was above 25 percent; and, in 2007, only Mississippi was above 30 percent. 25.8 million people in the USA have diabetes. 245 billion USD: Total costs of diagnosed diabetes in the United States in 2012. 176 million USD for direct medical costs. (source: diabetes.org). What I am saying is that it is great news for XENERS and PSA-Oxyntomodulin. NASDAQ later this year and BOOM! Do the numbers on just this one drug. Pass another fat burger please.

That's gotta be a money-spinner for us.

Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity. http://online.wsj.com/article/PR-CO-20140512-911739.html

No. Prepared to wait for the NASDAQ rocket.

I'm smiling. Many thanks! You don't happen to have the recipe for chilly crab that I used to enjoy outside in Thomson Gardens do you?

So, according to the BOD, the SP is expected to be around 300-400p by 2016? Great news !

Xenetic also announced the appointment of Roman Knyazev, an experienced financial professional, to the Board of Directors. Mr. Knyazev is a senior investment manager at RUSNANO (the Russian state-sponsored nanotechnology fund) and is an appointee of SynBio, a RUSNANO-controlled entity and currently the largest shareholder of Xenetic. He has worked at RUSNANO for the last 5 years, prior to which time he worked at PriceWaterhouseCoopers from 2007 to 2009 and at Deloitte Consulting from 2005 to 2007. He is a member of the SynBio Board of Directors and is a nominated Non-Executive Director being appointed pursuant to the agreement entered into between Xenetic and SynBio, whereby SynBio is entitled to nominate two directors to the Xenetic Board subject to SynBio holding not less than 40% of the Company's equity share capital. Mr. Knyazev is also a Deputy Chairman at Pharmsynthez, PETAR and Nanolek. - See more at: http://globenewswire.com/news-release/2014/05/05/632896/10079886/en/Xenetic-Biosciences-Appoints-Industry-Veteran-Mark-Leuchtenberger-as-Chairman-of-the-Board-of-Directors.html#sthash.XjzuPBWX.dpuf